Current Affairs - Science

Tentative approval was granted by the U.S. Food and Drug Administration for a generic version of Erdafitinib in multiple strengths, expanding access to an important cancer treatment in the US market. Natco Pharma secured this approval for the drug equivalent to Janssen’s Balversa. Erdafitinib is prescribed for adults with unresectable or metastatic urothelial carcinoma that carries specific FGFR3 genetic alterations. This development highlights Natco Pharma’s growing presence in the oncology segment and reflects its focus on making advanced cancer therapies more affordable and accessible to patients through high-quality generic medicines.

The rare mushroom species Hemileccinum indicum was discovered in the oak forests of Uttarakhand, specifically in the Dhakuri region of Bageshwar district at elevations above 2,600 metres. This finding is scientifically significant as it marks the first recorded presence of the genus Hemileccinum in India. The discovery was made through systematic macrofungal surveys and confirmed using advanced molecular phylogenetic analysis. Beyond taxonomy, the species plays an important ecological role by forming symbiotic relationships with oak trees, enhancing nutrient cycling and forest health, and highlighting the rich yet underexplored fungal biodiversity of the Himalayan region.

Novo Medi Sciences introduced NEXIPOX PLUS®, an advanced Varicella (chickenpox) vaccine tailored for Indian clinical and environmental conditions. The vaccine uses a 2X trehalose-based stabiliser system, which enhances viral stability, preserves potency, and reduces allergenic reactions associated with gelatin and mannitol. This launch represents India’s first upgraded formulation of the Varicella vaccine, reflecting innovation in vaccine development and addressing the need for safer, more effective immunisation options in the country. The product is positioned to improve vaccination outcomes and public health protection.

Menkes disease is a rare genetic disorder caused by a mutation that disrupts copper transport in the body, leading to severe developmental and physiological issues in affected children. Zycubo (copper histidinate) is the first FDA-approved treatment for this condition. Administered by injection, it bypasses the defective copper absorption mechanism and significantly improves survival, especially when started within four weeks of birth. Clinical trials showed that early-treated children had a 78% lower risk of death. Monitoring is important due to possible copper toxicity, emphasizing careful management during treatment.

VCare launched the Bengaluru Centre of Excellence to introduce a breakthrough approach in aesthetic care through its Single-Day Facial Architecture. The centre brings together a Korean-inspired treatment protocol that integrates seven advanced laser technologies using a 3D methodology. This innovation is designed to deliver visible improvements starting from the first day, with sustained results over a 90-day period. The initiative is led by founder E Carolin Praba and aligns with the brand’s broader vision of expanding its network of over 80 clinics across major cities, including Bengaluru and Hyderabad.